JB Pharma Celebrates a Year of Exceptional Growth and Strong Performance, Driven by a Vision for Global Health
Mumbai (Maharashtra), June 6, 2023 — JB Pharma, recognized as the fastest-growing company in the Indian pharmaceutical market, celebrates its first anniversary since launching its new brand identity, “Good People for Good Health.” This milestone underscores the company’s steadfast commitment to promoting health worldwide and enriching the lives of patients. With a focus on people, products, and results, JB Pharma has made significant strides in transforming the healthcare landscape in India and beyond.
A Year of Market-Leading Performance
Reflecting on this achievement, Mr. Nikhil Chopra, CEO & Whole-Time Director of JB Pharma, stated, “While we continue to scale new heights, our core values of simplicity, reliability, and agility remain at the heart of our operations. We are committed to maintaining simplicity in our actions, reliability in our relationships, and agility in adapting to the evolving healthcare industry.”
In their recent financial announcement for Q4FY23, JB Pharma reported robust growth across key metrics. The company recorded revenues of INR 3,149 crores, marking a 30% increase. Operating EBITDA saw a 26% rise, reaching INR 765 crores, while Profit After Tax grew by 6% to INR 410 crores. This consistent upward trajectory continued throughout the year, with quarterly revenues of INR 762 crores, reflecting a 22% increase.
Extensive Reach Across India and International Markets
JB Pharma has significantly expanded its footprint, now reaching over 6 lakh pharmacies and serving 40+ regulated markets globally. The company has made notable progress in various therapeutic areas, including pediatrics, cardiology, respiratory, anti-infectives, gastroenterology, nephrology, and gynecology. For the second consecutive year, JB Pharma has been recognized as the fastest-growing pharmaceutical company in India (IQVIA MAT Mar’23).
Strong Domestic Business Performance
JB Pharma’s domestic formulations business delivered outstanding results, with Q4 revenue of INR 380 crores, reflecting a 29% growth, and FY23 revenue of INR 1,640 crores, representing a 38% increase. Key brands such as Rantac, Cilacar, Metrogyl, Nicardia, and Sporlac have significantly contributed to the company’s success. Notably, JB Pharma ranks among the top 10 players in the cardiology segment and is a leading name in the probiotics market, with Sporlac being one of the fastest-growing brands in India.
Growth in Contract Development and Manufacturing Operations (CDMO)
On the international front, JB Pharma’s CDMO business saw remarkable growth, with a 16% increase in Q4 revenue to INR 382 crores and a 22% rise to INR 1,509 crores for FY23. The company’s CDMO division, a global leader in the manufacturing of herbal and medicated lozenges, closed the year with revenues surpassing INR 400 crores, maintaining a consistent quarterly run rate of INR 100 crores. JB Pharma produces over 70 products in various formats, catering to nearly 7% of the world’s population.
People-Centric Initiatives and Corporate Culture
JB Pharma is also committed to nurturing its workforce, introducing more than 50 people-centric initiatives to enhance learning and development while promoting work-life balance. The company launched the JBCares app, a 360-degree wellness initiative, and the LEAP program to train and develop future leaders. Women’s representation at JB Pharma grew by 20.6% from 2019-20, further fostering an inclusive environment that prioritizes equality, health, and well-being.
Sustainability and Environmental Focus
As part of its dedication to sustainability, JB Pharma continues to make significant progress in reducing emissions and achieving its environmental goals for FY24. The company released its inaugural sustainability report for FY22, outlining its efforts toward sustainable practices in operations.
Looking Forward
With a robust business model and a clear focus on innovation, JB Pharma remains well-positioned to continue its leadership in the Indian pharmaceutical market. The company’s growth trajectory, coupled with its dedication to healthcare excellence and sustainability, ensures a promising future for both the organization and its stakeholders.
For media inquiries or more information, contact:
pr.error.rectification[at]gmail.com.
